Netherlands-based InteRNA Technologies, a biopharma company that develops microRNA (miRNA)-based therapeutics for oncology, has announced the close of its Series B round with extended funding of €18.5M in total.
Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer.